Zwitterionic Peptide Engineeringfor Precise Radiopharmaceutical Targeting
Klayon Therapeutics develops radiopharmaceuticals powered by Z-ION ARK™,
a zwitterionic peptide-based platform that creates a hydration barrier
to reduce non-specific binding. This enables highly selective tumor targeting
with improved safety and pharmacokinetics.
Our Approach
Precision Tumor Targeting
Enabled by the Z-ION ARK™ platform, our approach improves targeting precision of radiopharmaceuticals.
Reduced Systemic Toxicity
Z-ION ARK™ minimizes non-specific uptake in healthy tissues, improving overall safety.
Flexible Ligand Strategy
Z-ION ARK™ supports both internally developed and externally sourced ligands, enabling broad application across oncology targets.
Z-ION ARK™ Platform
Z-ION ARK™ is Klayon's proprietary radiopharmaceutical platform based on zwitterionic peptide engineering, designed to modulate in vivo interactions and optimize pharmacokinetics.
Zwitterionic Architecture
Charge-balanced peptide structures within Z-ION ARK™ reduce unintended interactions with biological components, enabling more controlled in vivo behavior.
Hydration Barrier Formation
Z-ION ARK™ forms structured hydration layers that limit non-specific protein binding and improve circulation characteristics in vivo.
Optimized Biodistribution
By reducing off-target accumulation, Z-ION ARK™ enables more favorable tumor-to-normal tissue distribution and improved targeting performance.
Platform Modularity
Z-ION ARK™ is compatible with diverse isotopes and targeting ligands, supporting flexible drug design across multiple radiopharmaceutical applications.
Conventional radiopharmaceuticals often suffer from non-specific interactions and unfavorable pharmacokinetics, leading to off-target accumulation and limited therapeutic window.
Z-ION ARK™ leverages zwitterionic peptide engineering to reduce non-specific binding and improve pharmacokinetics, enabling more precise tumor targeting and a wider therapeutic window.
Leadership
Jaden H. Chang
Founder & Chief Executive OfficerJaden H. Chang is the Founder and Chief Executive Officer of Klayon Therapeutics, a radiopharmaceutical platform company focused on advancing precision oncology. He leads the company's overall strategy, operations, and development of zwitterionic peptide engineering, the foundation of the Z-ION ARK™ platform.
Dr. Chang received his Ph.D. in Chemical and Bio-Engineering from Seoul National University and completed postdoctoral research at the BSAC Research Center, UC Berkeley. His research has focused on the development of zwitterionic peptide engineering, which forms the foundation of Klayon's technology. He has authored over 30 scientific publications and filed multiple patents in this field.
Under his leadership, Klayon is advancing its radiopharmaceutical platform toward clinical development, with a focus on improving tumor targeting and reducing off-target toxicity.
Collaboration Opportunities
We collaborate with pharmaceutical companies, academic institutions, and investors to expand applications of the Z-ION ARK™ platform across radiopharmaceutical development.
Contact Us
Headquarters
550 Congressional Blvd, Suite 350
Carmel, IN 46032, USA